Publications by authors named "R Vidra"

Ecosystem restoration has historically been viewed as an ecological endeavor, but restoration possesses significant, yet largely untapped, potential as a catalyst for personal and social transformation. We highlight the opportunity for restoration to enhance community resilience by increasing agency and collective action and countering the pervasive perception that we are powerless witnesses to environmental decline. In this perspective, we take a "bright spots" approach and highlight successful examples of ecosystem restoration that have helped to nurture a sense of place, foster optimism, and cultivate stronger and more diverse social networks.

View Article and Find Full Text PDF

(1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with paclitaxel. The present study aimed to evaluate the efficacy and safety of ramucirumab in the Romanian population during every-day clinical practice. (2) Methods: A two-center, retrospective, observational study evaluated patients with metastatic gastric and GEJ cancer treated with ramucirumab monotherapy or associated with paclitaxel.

View Article and Find Full Text PDF

Background: During the European Society for Medical Oncology (ESMO) Congress 2022, outcome data of a great number of clinical trials were presented. For the attending medical oncologist, it is important to structure these data in a way that facilitates a trade-off between treatment burden and benefit.

Materials And Methods: To illustrate this, we carried out a narrative non-systematic review of 12 selected oral presentations with potential impact on future daily practice, focusing on trial methodology, possible study flaws, reported clinical benefit and implementability.

View Article and Find Full Text PDF

Patients with cancer are a high-priority population for COVID-19 vaccination, as per guideline recommendations. The present cross-sectional study was performed to assess the perception of patients with cancer from Romania regarding COVID-19 vaccines. The study included 932 patients with solid and hematologic malignancies.

View Article and Find Full Text PDF
Article Synopsis
  • Approximately 10,000 women are diagnosed with breast cancer and 2,000 with ovarian cancer each year in Romania, but there are few genetic studies focused on identifying high-risk patients in the population.
  • Researchers evaluated 490 women (250 with breast cancer and 240 with ovarian cancer) using Next-Generation Sequencing to examine for harmful mutations in the BRCA1 and BRCA2 genes.
  • The study found a significant number of patients with BRCA mutations: 47% of breast cancer patients and 25% of ovarian cancer patients, identifying specific mutation variants that could help in genetic testing and risk assessment in the Romanian population.*
View Article and Find Full Text PDF